For laboratory research use only - not for human consumption

Compound hub ยท Retatrutide

Retatrutide side effects: what trials and regulators have recorded

Gut effects were the most common side effects in the 80-week TRIUMPH-2 trial of 1,152 adults with type 2 diabetes. The developer funded the trial. Diarrhoea affected 27% to 34% of people across the three retatrutide arms, against 13% on placebo. Nausea affected 14% to 28%, against 8% (Bellido et al., The Lancet, 2026). The TGA reported on 14 September 2026 that neither it nor a similar overseas regulator has approved retatrutide. So no approved label from those regulators lists its side effects.

Published 2026-10-14Updated 2026-10-14Written by Form Laboratories research team12 min read

Every medicine you have ever taken came with a leaflet. It listed what went wrong for some people. Retatrutide has no leaflet, because the TGA reports that no comparable regulator has approved it. What exists instead is a scattered record of trial papers, registry tables and regulator alerts. Each piece covers only part of the picture.

This page is part of the retatrutide hub. It collects what those records say about retatrutide's side effects. The study, the size and the comparison group sit beside each figure. Results on how well it works are on the study findings page. Nothing here is medical advice. It describes records, not any one person's experience.

Key facts

Key facts for Retatrutide side effects: what trials and regulators have recorded
Common nameretatrutide
Research codeLY3437943
Most frequent side effects in TRIUMPH-2Nausea, diarrhoea, vomiting and constipation (1,152 adults with type 2 diabetes; Bellido et al., The Lancet, 2026).
TRIUMPH-2 diarrhoea27% to 34% across three retatrutide arms, against 13% on placebo (TRIUMPH-2, developer-funded; Bellido et al., The Lancet, 2026).
TRIUMPH-2 nausea14% to 28% across three retatrutide arms, against 8% on placebo (TRIUMPH-2, developer-funded; Bellido et al., The Lancet, 2026).
TRIUMPH-2 altered skin sensation (dysaesthesia)4% to 7%, against 1% on placebo (TRIUMPH-2, developer-funded; Bellido et al., The Lancet, 2026).
TRIUMPH-2 stopped treatment because of side effects or death4%, 12% and 8% across the retatrutide arms, against 5% on placebo (TRIUMPH-2, developer-funded; Bellido et al., The Lancet, 2026).
Phase 2 obesity trial, serious events10 of 267 people on the drug and 3 of 70 on placebo (338 adults). It was a small developer-funded trial that cannot show rare events (ClinicalTrials.gov NCT04881760).
Regulator status as of 14 October 2026Not approved by the TGA or a similar overseas regulator (TGA safety alert, 14 September 2026).
TGA test of one product sold as retatrutideUndeclared semaglutide and no retatrutide in that one product. A single sample does not show how common mislabelled products are (TGA safety alert, 14 September 2026).
Victorian health alert, 19 June 2026Six reported cases of acute liver injury in people who had used products labelled retatrutide. A contaminant is suspected, not confirmed. Case reports cannot show how common the injury is (Victorian health alert, 19 June 2026).
Records checked14 October 2026
ClinicalTrials.gov NCT04881760The Lancet 2026 (TRIUMPH-2)NEJM 2023The Lancet 2023

What are the side effects of retatrutide?

The small Phase 2 obesity trial of 338 adults was funded by the developer. Its registry lists nausea in 31% of people on the drug, vomiting in 12%, diarrhoea in 14% and constipation in 11%. On placebo the figures were 11%, 1%, 11% and 3%. The registry uses a 5% reporting threshold, so rarer events are left out (ClinicalTrials.gov NCT04881760). In the 80-week TRIUMPH-2 trial of 1,152 adults with type 2 diabetes, nausea affected 14% to 28% of people across the three retatrutide arms, against 8% on placebo. The developer funded that trial too (Bellido et al., 2026).

In the Phase 2 obesity paper of 338 adults, the most common side effects were gut events. They grew with the trial arm level and were mostly mild to moderate. The developer funded the trial (Jastreboff et al., 2023). In the Phase 2 trial of 281 adults with type 2 diabetes, mild to moderate gut events affected 67 of 190 people on the drug (35%). On placebo it was 6 of 45 (13%). The developer funded this small early-phase trial (Rosenstock et al., 2023).

The table below sets out the Phase 2 registry events side by side. The registry lists events reported by 5% or more of people in any arm, so rarer events do not appear. The pooled counts add the arm counts that the registry reports. For the same question about an approved medicine, tirzepatide's side effects are set out the same way.

TGA safety alert, 14 September 2026NEJM 2026 (TRIUMPH-1)The Lancet 2026 (TRIUMPH-2)

Evidence limits

Is retatrutide safe?

No trial or regulator gives retatrutide a yes-or-no safety verdict. The TGA reported on 14 September 2026 that neither it nor a similar overseas regulator has approved retatrutide. So this page found no approved label from those regulators (TGA safety alert, 14 September 2026). The longest obesity trial papers read for this page ran 80 weeks (Jastreboff et al., 2026; Bellido et al., 2026). Trials of this size count common side effects well. They can miss rare ones. Eli Lilly funded and sponsored every trial cited on this page.

Two limits shape every number below. First, we read the 2026 Phase 3 papers as abstracts only. So their full side-effect tables are not reported here. Second, a trial result describes trial drug given under supervision. It does not describe a product from any other source.

The last section of this page reports a different kind of record. Regulator alerts and case reports describe products sold as retatrutide. They cannot give a frequency. That is why they sit apart from the trial figures.

ClinicalTrials.gov NCT04881760The Lancet 2026 (TRIUMPH-2)The Lancet 2026 (TRANSCEND-T2D-1)The Lancet 2023

What serious events have retatrutide trials recorded?

The Phase 2 obesity registry lists serious events in 10 of 267 people on the drug (4%) and 3 of 70 on placebo (4%). One death was in a retatrutide arm. The trial was small and funded by the developer. It cannot show rare events or establish safety (ClinicalTrials.gov NCT04881760). The same registry lists one case of acute pancreatitis in the highest arm. It lists one case of acute cholecystitis, which is gallbladder inflammation, and one of acute kidney injury. These counts are too small to show how often such events occur. In TRIUMPH-2, a developer-funded trial of 1,152 adults with type 2 diabetes, seven people died. Six were on retatrutide and one was on placebo. The investigators judged every death unrelated to the study intervention (Bellido et al., 2026).

TRANSCEND-T2D-1 was a 40-week developer-funded trial of 537 adults with type 2 diabetes. It reported two deaths, both in the lowest retatrutide arm. The investigators judged both unrelated to the study drug. There was no severe hypoglycaemia (Bajaj et al., 2026). The Phase 2 trial of 281 adults with type 2 diabetes reported no deaths and no severe hypoglycaemia. It was a short early-phase trial that cannot show rare events (Rosenstock et al., 2023).

The Phase 2 obesity registry lists increased lipase in 15 of 267 people on the drug, against 2 of 70 on placebo. It lists increased amylase in 5, against 2. These are blood-test results. They do not establish pancreatitis, because the registry does not say how many involved symptoms (ClinicalTrials.gov NCT04881760).

NEJM 2023The Lancet 2026 (TRIUMPH-2)ClinicalTrials.gov NCT04881760European Journal of Clinical Pharmacology 2026Kidney International Reports 2025

What risks have retatrutide studies recorded besides gut effects?

The Phase 2 obesity paper reports faster heart rates in its 338 adults. They grew with the trial arm level. They peaked at 24 weeks and fell afterwards. The developer funded the trial (Jastreboff et al., 2023). In TRIUMPH-2, a developer-funded trial of 1,152 adults with type 2 diabetes, hypotension affected 1%, 5% and 6% of people across the retatrutide arms, against under 1% on placebo. Hypotension is low blood pressure. Dysaesthesia affected 4%, 6% and 7%, against 1%. Dysaesthesia is an altered or burning skin sensation. These results are for that trial only (Bellido et al., 2026).

The Phase 2 obesity registry lists hypertension in 14 of 267 people on the drug, against 2 of 70 on placebo. It lists hypotension in 6, against 0. It lists hyperaesthesia in 7, against 1. That is raised skin sensitivity. It lists allodynia in 4, against 0. That is pain from a light touch. Only events reported by 5% or more of people in any arm are counted (ClinicalTrials.gov NCT04881760).

A 2026 study looked at reports of dysaesthesia in a safety database called VigiBase. It also used French case notes and a literature review. Its abstract gives no report count. It covered approved GLP-1 medicines and tirzepatide, not retatrutide. Reports like these cannot give a frequency or prove cause (Laroche et al., 2026). On the kidneys, a post hoc analysis looked at the two Phase 2 trials, with 281 adults with type 2 diabetes and 338 with overweight or obesity. It was run after the trials. The authors included developer employees. It found eGFR, a measure of kidney filtering, unchanged in people with type 2 diabetes and higher in people with obesity (Heerspink et al., 2025). The hair-loss question is covered on the study findings page.

The Lancet 2026 (TRIUMPH-2)The Lancet 2026 (TRANSCEND-T2D-1)ClinicalTrials.gov NCT04881760

How many people stopped retatrutide trials because of side effects?

In the 80-week TRIUMPH-2 trial of 1,152 adults with type 2 diabetes, some people stopped for good because of a side effect or death. The shares were 4%, 12% and 8% across the three retatrutide arms, against 5% on placebo. The developer funded that trial (Bellido et al., 2026). TRANSCEND-T2D-1 was a 40-week trial of 537 adults with type 2 diabetes. In it, 2% to 5% stopped because of side effects with retatrutide and 0% with placebo. It counted in a different way from TRIUMPH-2, so the two are not similar (Bajaj et al., 2026). The Phase 2 obesity registry lists a side effect as the reason for leaving the study for 6 people on the drug and none on placebo. That trial was small and funded by the developer. It cannot show how often rarer events lead to stopping (ClinicalTrials.gov NCT04881760).

The counts differ between trials because the trials differ in length, population and counting rules. TRIUMPH-2 combined side effects and deaths into one measure. TRANSCEND-T2D-1 counted side effects alone (Bellido et al., 2026; Bajaj et al., 2026). A percentage only means something when it stays tied to the trial that produced it.

TGA safety alert, 14 September 2026Victorian health alert, 19 June 2026Drug and Alcohol Review 2026BMJ Case Reports 2026

What have Australian authorities reported about products sold as retatrutide?

Australian authorities have issued two warnings about products sold as retatrutide. On 14 September 2026 the TGA reported one consumer with uncontrollable vomiting. It tore the oesophagus, and the person needed hospital care. A lab tested the unmarked vial. It held no retatrutide. It held undeclared semaglutide at about eight times the level in semaglutide products on the Australian Register of Therapeutic Goods. This report covers one person and one sample. It does not show how common such events are (TGA safety alert, 14 September 2026). On 19 June 2026 the Victorian Chief Health Officer reported six cases of acute liver injury since January 2026. The people had used products labelled retatrutide. A contaminant may be involved. The alert covers case reports. The cause was not established (Victorian health alert, 19 June 2026).

A 2026 lab study tested three products sold as retatrutide in Australia. All three matched the expected molecular weight. The measured peptide content ranged from 51% to 190% of the labelled amount. Three products cannot show what the wider market holds (Piatkowski et al., Drug and Alcohol Review, 2026). A 2026 case report describes one woman in her mid-20s. She had five days of nausea and vomiting after exposure to an unchecked product reported to contain retatrutide. It cleared within a week. Causality was probable on the Naranjo scale. A single case cannot show how common this is (Buzzi et al., BMJ Case Reports, 2026).

These records describe specific products and specific people. They cannot show how common such harms are, and they are not trial data. Retatrutide's legal status in Australia sets out the TGA statements with their dates.

The Lancet 2022Cell Metabolism 2022ClinicalTrials.gov NCT04143802

Which clinical trial paper reports retatrutide's half-life?

The Phase 1b trial of 72 adults with type 2 diabetes reports retatrutide's half-life as about six days. It also reports exposure that rose in step with the dose. The developer funded this small early-phase trial. It describes that group only (Urva et al., The Lancet, 26 November 2022). The registry lists the trial as enrolling those 72 adults at four US centres from 18 December 2019 to 28 December 2020 (ClinicalTrials.gov NCT04143802). The first-in-human study in Cell Metabolism reports a separate profile in 45 healthy adults. It was a small single-exposure study. It describes those adults only (Coskun et al., 2022).

Pharmacokinetics means what the body does to a compound over time. The pharmacokinetics page sets out the half-life range, the time to peak level and the gaps in the record. One gap is that none of the sources checked had a human metabolism study.

The Lancet 2026 (TRIUMPH-2)NEJM 2023

Do these side-effect records apply to research-use retatrutide?

No. The trial figures on this page come from trial drug product given to enrolled people. Trial staff screened and monitored them (Bellido et al., 2026; Jastreboff et al., 2023). The regulator and case-report records describe products from outside trials. Their contents were unchecked when people were exposed, although the TGA later tested one of them in a laboratory (TGA safety alert, 14 September 2026). Research-use retatrutide is a laboratory compound. Research material is not a medicine. It is not a substitute for one. It is not for human or animal use. No side-effect record here describes it. These records cannot show the effects of other products.

Lab work uses reference material that comes with paperwork. This site's retatrutide reference material listing is freeze-dried stock for the lab. The retatrutide research guide covers the compound itself.

Comparison

Side effects listed in the retatrutide Phase 2 obesity trial (NCT04881760; 338 adults; 48 weeks; developer-funded; results first posted 13 September 2023). Retatrutide figures add the six retatrutide arms from the registry. The registry lists only events reported by 5% or more of people in any arm. This is one trial, so it is not a verdict on safety.

Comparison: Retatrutide side effects: what trials and regulators have recorded
EventRegistry count in this one trial (retatrutide arms pooled, 267 people, against placebo, 70 people)
Nausea83 of 267 people on the drug (31%) against 8 of 70 on placebo (11%).
Decreased appetite56 of 267 people on the drug (21%) against 6 of 70 on placebo (9%).
Diarrhoea37 of 267 people on the drug (14%) against 8 of 70 on placebo (11%).
Vomiting33 of 267 people on the drug (12%) against 1 of 70 on placebo (1%).
Constipation30 of 267 people on the drug (11%) against 2 of 70 on placebo (3%).
Fatigue19 of 267 people on the drug (7%) against 3 of 70 on placebo (4%).
Increased lipase (a pancreas enzyme)15 of 267 people on the drug (6%) against 2 of 70 on placebo (3%).
Hypertension14 of 267 people on the drug (5%) against 2 of 70 on placebo (3%).
Gastro-oesophageal reflux13 of 267 people on the drug (5%) against 1 of 70 on placebo (1%).
Dizziness12 of 267 people on the drug (4%) against 2 of 70 on placebo (3%).
Headache11 of 267 people on the drug (4%) against 0 of 70 on placebo (0%).
Hypotension6 of 267 people on the drug (2%) against 0 of 70 on placebo (0%).

FAQ

What are the potential side effects of retatrutide?

In TRIUMPH-2, a developer-funded trial of 1,152 adults with type 2 diabetes, diarrhoea affected 27% to 34% of people on the drug, against 13% on placebo. Dysaesthesia affected 4% to 7%, against 1%. These results are for that trial only (Bellido et al., 2026). Trial lists are not a full label. The TGA reported on 14 September 2026 that neither it nor a similar international regulator has approved retatrutide.

Is retatrutide safe?

No trial or regulator gives a yes-or-no answer. The TGA reported that it has not approved retatrutide, and neither has a similar overseas regulator. The longest obesity trials here ran 80 weeks. The sponsor funded every trial (TGA safety alert, 14 September 2026; Bellido et al., The Lancet, 2026).

What are the recorded risks of retatrutide?

The Phase 2 obesity paper of 338 adults recorded faster heart rates. The developer funded the trial (Jastreboff et al., 2023). TRIUMPH-2 recorded low blood pressure and altered skin sensation in 1,152 adults with type 2 diabetes. These results are for that trial only (Bellido et al., 2026). The 338-adult Phase 2 obesity registry lists serious events in 4% of people on the drug and 4% on placebo. The trial was too small to show rare events (ClinicalTrials.gov NCT04881760). The TGA found no retatrutide in one laboratory-tested product sold as retatrutide. That is a single sample and cannot show how often products are mislabelled (TGA safety alert, 14 September 2026).

Has retatrutide been linked to liver injury?

Victoria's Chief Health Officer reported six cases of acute liver injury in people who had used products labelled retatrutide. The alert said a contaminant may be involved. It is about case reports and does not establish cause (Victorian health alert, 19 June 2026). The trial papers read for this page do not report liver injury as a main finding. We did not read the full tables.

Does retatrutide affect the kidneys?

A post hoc analysis looked at the two Phase 2 trials (281 adults with type 2 diabetes and 338 with overweight or obesity). It was run after the trials, not planned as their main question. The authors included developer employees. eGFR was unchanged in people with type 2 diabetes and higher in people with obesity. Albumin in urine fell (Heerspink et al., 2025).

Can retatrutide cause hair loss?

No retatrutide hair-loss rate appears in the sources read for this page. Two posted side-effect tables list events reported by 5% or more of people in any arm. They are for the Phase 2 obesity trial of 338 adults (ClinicalTrials.gov NCT04881760) and the Phase 2 type 2 diabetes trial of 281 adults (ClinicalTrials.gov NCT04867785). Neither lists hair loss. That does not establish how often it happens. The question is set out on the study findings page.

What is retatrutide's half-life?

About six days in the 72-adult Phase 1b trial in type 2 diabetes. The pharmacokinetics were also dose proportional. It was a small early-phase trial funded by the developer (Urva et al., 2022).

Citations

11 sources
  1. Bellido V et al. The Lancet. 2026;408(10563):1455-1472.
    doi:10.1016/S0140-6736(26)01861-1

  2. Jastreboff AM et al. New England Journal of Medicine. 2023;389(6):514-526.
    doi:10.1056/NEJMoa2301972

  3. Jastreboff AM et al. New England Journal of Medicine. 2026, online 29 September (TRIUMPH-1).
    doi:10.1056/NEJMoa2604169

  4. Bajaj HS et al. The Lancet. 2026;407(10546):2402-2413.
    doi:10.1016/S0140-6736(26)00967-0

  5. Rosenstock J et al. The Lancet. 2023;402(10401):529-544.
    doi:10.1016/S0140-6736(23)01053-X

  6. Urva S et al. The Lancet. 2022;400(10366):1869-1881.
    doi:10.1016/S0140-6736(22)02033-5

  7. Coskun T et al. Cell Metabolism. 2022;34(9):1234-1247.e9.
    doi:10.1016/j.cmet.2022.07.013

  8. Heerspink HJL et al. Kidney International Reports. 2025;10(6):1980-1992.
    doi:10.1016/j.ekir.2025.03.049

  9. Laroche ML et al. European Journal of Clinical Pharmacology. 2026;82(6).
    doi:10.1007/s00228-026-04079-7

  10. Piatkowski T et al. Drug and Alcohol Review. 2026;45(6):e70231.
    doi:10.1111/dar.70231

  11. Buzzi RM et al. BMJ Case Reports. 2026;19(10).
    doi:10.1136/bcr-2026-276106

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Continue

Retatrutide reference material

Research use only, not for human or animal use.

Read the retatrutide research guide

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease